These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 36995019)
1. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention. Mahapatra S; Jonniya NA; Koirala S; Ursal KD; Kar P J Biomol Struct Dyn; 2023; 41(22):13509-13533. PubMed ID: 36995019 [TBL] [Abstract][Full Text] [Related]
2. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications. Dianat-Moghadam H; Teimoori-Toolabi L Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505 [TBL] [Abstract][Full Text] [Related]
3. Future applications of FGF/FGFR inhibitors in cancer. Ghedini GC; Ronca R; Presta M; Giacomini A Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878 [TBL] [Abstract][Full Text] [Related]
4. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Ronca R; Giacomini A; Rusnati M; Presta M Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971 [TBL] [Abstract][Full Text] [Related]
8. Advances and challenges in targeting FGFR signalling in cancer. Babina IS; Turner NC Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Liu G; Chen T; Ding Z; Wang Y; Wei Y; Wei X Cell Prolif; 2021 Apr; 54(4):e13009. PubMed ID: 33655556 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression. Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of FGFR-mediated carcinogenesis. Ahmad I; Iwata T; Leung HY Biochim Biophys Acta; 2012 Apr; 1823(4):850-60. PubMed ID: 22273505 [TBL] [Abstract][Full Text] [Related]
12. Recent developments and advances of FGFR as a potential target in cancer. Xue WJ; Li MT; Chen L; Sun LP; Li YY Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580 [TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Presta M; Chiodelli P; Giacomini A; Rusnati M; Ronca R Pharmacol Ther; 2017 Nov; 179():171-187. PubMed ID: 28564583 [TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Parish A; Schwaederle M; Daniels G; Piccioni D; Fanta P; Schwab R; Shimabukuro K; Parker BA; Helsten T; Kurzrock R Cell Cycle; 2015; 14(13):2121-8. PubMed ID: 25950492 [TBL] [Abstract][Full Text] [Related]
15. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Hierro C; Rodon J; Tabernero J Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127 [TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Helsten T; Schwaederle M; Kurzrock R Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133 [TBL] [Abstract][Full Text] [Related]
17. Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents. Herbert C; Lassalle G; Alcouffe C; Bono F Pharm Pat Anal; 2014; 3(6):585-612. PubMed ID: 25489913 [TBL] [Abstract][Full Text] [Related]
18. The role of fibroblast growth factors and their receptors in prostate cancer. Kwabi-Addo B; Ozen M; Ittmann M Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447 [TBL] [Abstract][Full Text] [Related]
19. Non-canonical fibroblast growth factor signalling in angiogenesis. Murakami M; Elfenbein A; Simons M Cardiovasc Res; 2008 May; 78(2):223-31. PubMed ID: 18056763 [TBL] [Abstract][Full Text] [Related]
20. FGFR-TKI resistance in cancer: current status and perspectives. Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]